Fluctuations in pathogenic CD4+ T-cell subsets in a murine sclerodermatous model of chronic graft-versus-host disease

Immunological Investigations

Volumn 43, Issue 1, 2014, Pages 41-53

  Lim, Ji Young ^a   Cho, Byung Sik ^a   Min, Chang Ki ^a   Park, Gyeongsin ^a   Kim, Yoo Jin ^a   Chung, Nak Gyun ^a   Jeong, Dae Chul ^a   Min, Woo Sung ^a  

^a The Catholic University of Korea   (South Korea)

Author keywords

Chronic graft versus host disease; Th1; Th17

Indexed keywords

CD4 ANTIGEN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE MARROW CELL; CD4+ T LYMPHOCYTE; CHRONIC GRAFT VERSUS HOST DISEASE; CONTROLLED STUDY; DISEASE COURSE; FEMALE; FLOW CYTOMETRY; GRAFT RECIPIENT; LIVER; LIVER INJURY; MOUSE; NONHUMAN; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; SCORING SYSTEM; SKINFOLD THICKNESS; SPLEEN CELL; T LYMPHOCYTE SUBPOPULATION; TH1 CELL; TH17 CELL; TH2 CELL; TIME;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; FEMALE; GRAFT VS HOST DISEASE; LIVER; MICE; SKIN; T-LYMPHOCYTE SUBSETS; T-LYMPHOCYTES, HELPER-INDUCER;

EID: 84889763045     PISSN: 08820139     EISSN: 15324311     Source Type: Journal    
DOI: 10.3109/08820139.2013.843191     Document Type: Article

References (36)

1. Anderson BE, McNiff JM, Jain D, et al. (2005). Distinct roles for donor-And hostderived antigen-presenting cells and costimulatory molecules in murine chronic graft-versus-host disease: Requirements depend on target organ. Blood, 105, 2227-34
2. Broady R, Yu J, Chow V, et al. (2010). Cutaneous GVHD is associated with the expansion of tissue-localized Th1 and not Th17 cells. Blood, 116, 5748-51
3. Carlson MJ, West ML, Coghill JM, et al. (2009). In vitro-differentiated TH17 cells mediate lethal acute graft-versus-host disease with severe cutaneous and pulmonary pathologic manifestations. Blood, 113, 1365-74
4. Chen X, Das R, Komorowski R, et al. (2010). Interleukin 17 is not required for autoimmune-mediated pathologic damage during chronic graft-versus-host disease. Biol Blood Marrow Transplant, 16, 123-8
5. Cho BS, Lim JY, Yahng SA, et al. (2012). Circulating IL-17 levels during the peritransplant period as a predictor for early leukemia relapse after myeloablative allogeneic stem cell transplantation. Annals of hematology, 91, 439-48
6. Cooke KR, Kobzik L, Martin TR, et al. (1996). An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood, 88, 3230-9
7. Dander E, Balduzzi A, Zappa G, et al. (2009). Interleukin-17-producing T-helper cells as new potential player mediating graft-versus-host disease in patients undergoing allogeneic stem-cell transplantation. Transplantation, 88, 1261-72
8. Dong C. (2006). Diversification of T-helper-cell lineages: Finding the family root of IL-17-producing cells. Nat Rev Immunol, 6, 329-33
9. Fraser CJ, Bhatia S, Ness K, et al. (2006). Impact of chronic graft-versus-host disease on the health status of hematopoietic cell transplantation survivors: A report from the Bone Marrow Transplant Survivor Study. Blood, 108, 2867-73
10. Gooley TA, Chien JW, Pergam SA, et al. (2010). Reduced mortality after allogeneic hematopoietic-cell transplantation. N Engl J Med, 363, 2091-101
11. Gratwohl A, Baldomero H, Aljurf M, et al. (2010). Hematopoietic stem cell transplantation: A global perspective. JAMA, 303, 1617-24
12. Hill GR, Cooke KR, Teshima T, et al. (1998). Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest, 102, 115-23
13. Howell CD, De Victor D, Li J, et al. (1995). Liver T cell subsets and adhesion molecules in murine graft-versus-host disease. Bone Marrow Transplant, 16, 139-45
14. Iclozan C, Yu Y, Liu C, et al. (2010). T helper17 cells are sufficient but not necessary to induce acute graft-versus-host disease. Biol Blood Marrow Transplant, 16, 170-8
15. Jenq RR, van den Brink MR. (2010). Allogeneic haematopoietic stem cell transplantation: Individualized stem cell and immune therapy of cancer. Nat Rev Cancer, 10, 213-21
16. Kaplan DH, Anderson BE, McNiff JM, et al. (2004). Target antigens determine graftversus-host disease phenotype. J Immunol, 173, 5467-75
17. Kappel LW, Goldberg GL, King CG, et al. (2009). IL-17 contributes to CD4-mediated graft-versus-host disease. Blood, 113, 945-52
18. Kim J, Kim HJ, Park K, et al. (2007). Costimulatory molecule-Targeted immunotherapy of cutaneous graft-versus-host disease. Blood, 110, 776-82
19. Kolls JK, Linden A. (2004). Interleukin-17 family members and inflammation. Immunity, 21, 467-76
20. Lee JW, Joachim Deeg H. (2008). Prevention of chronic GVHD. Best Pract Res Clin Haematol, 21, 259-70
21. Lee SJ, Vogelsang G, Flowers ME. (2003). Chronic graft-versus-host disease. Biol Blood Marrow Transplant, 9, 215-33
22. Li J, Helm K, Howell CD. (1996). Contributions of donor CD4 and CD8 cells to liver injury during murine graft-versus-host disease. Transplantation, 62, 1621-8
23. McCormick LL, Zhang Y, Tootell E, Gilliam AC. (1999). Anti-TGF-beta treatment prevents skin and lung fibrosis in murine sclerodermatous graft-versus-host disease: A model for human scleroderma. J Immunol, 163, 5693-9
24. Miossec P, Korn T, Kuchroo VK. (2009). Interleukin-17 and type 17 helper T cells. N Engl J Med, 361, 888-98
25. Nishimori H, Maeda Y, Teshima T, et al. (2012). Synthetic retinoid Am80 ameliorates chronic graft-versus-host disease by down-regulating Th1 and Th17. Blood, 119, 285-95
26. Radojcic V, Pletneva MA, Yen HR, et al. (2010). STAT3 signaling in CD4 T cells is critical for the pathogenesis of chronic sclerodermatous graft-versus-host disease in a murine model. J Immunol, 184, 764-74
27. Ratajczak P, Janin A, Peffault de Latour R, et al. (2010). Th17/Treg ratio in human graft-versus-host-disease. Blood, 116, 1165-71
28. Sakoda Y, Hashimoto D, Asakura S, et al. (2007). Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease. Blood, 109, 1756-64
29. Svegliati S, Olivieri A, Campelli N, et al. (2007). Stimulatory autoantibodies to PDGF receptor in patients with extensive chronic graft-versus-host disease. Blood, 110, 237-41
30. Teshima T. (2011). Th1 and Th17 join forces for acute GVHD. Blood, 118, 4765-7
31. Wolff D, Gerbitz A, Ayuk F, et al. (2010). Consensus conference on clinical practice in chronic graft-versus-host disease (GVHD): First-line and topical treatment of chronic GVHD. Biol Blood Marrow Transplant, 16, 1611-28
32. Yi T, Chen Y, Wang L, et al. (2009). Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host disease. Blood, 114, 3101-12
33. Yi T, Zhao D, Lin CL, et al. (2008). Absence of donor Th17 leads to augmented Th1 differentiation and exacerbated acute graft-versus-host disease. Blood, 112, 2101-10
34. Zhang C, Todorov I, Zhang Z, et al. (2006). Donor CD4 T and B cells in transplants induce chronic graft-versus-host disease with autoimmune manifestations. Blood, 107, 2993-3001
35. Zhang Y, McCormick LL, Desai SR, et al. (2002). Murine sclerodermatous graftversus-host disease, a model for human scleroderma: Cutaneous cytokines, chemokines, and immune cell activation. J Immunol, 168, 3088-98
36. Zhou L, Askew D, Wu C, Gilliam AC. (2007). Cutaneous gene expression by DNA microarray in murine sclerodermatous graft-versus-host disease, a model for human scleroderma. J Invest Dermatol, 127, 281-92.